CSCO Conference Express Delivery of NSCLC Novel Immune Checkpoint Inhibitors Research Progress

Speaker introduction

Progress of new immune checkpoint inhibitors

In-depth studies of PD-1/PD-L1 inhibitors have covered the entire course of lung cancer, helping many patients prolong their life cycles

• Establish and improve the prediction system to accurately screen out the population suitable for immunosuppressive agents and long-term survival

• Drug resistance detection and response

• Explore more targets and treatment methods

   

TIGIT: Immunosuppressive cells in multiple links of the tumor immune cycle

TIGIT: Inhibition of tumor immune circulation

• Can inhibit NK cell-mediated cell killing

• Inhibit CD8 T cell-mediated killing and affect its initiation and differentiation

Triagolumab Combination Drug Research

TIGIT inhibitor: In the combined treatment group of Triagolumab and atelizumab, in the PD-L1 TPD>50% group, the ORR data was nearly 3 times higher than that of atelizumab alone

PFS has also improved, and the incidence of adverse reactions in the two groups is relatively close

Ociperlimab's research:

Ociperlimab has high activity and high affinity with TIGIT; it significantly enhances T cell response and promotes the synthesis and release of T cell IFN-y

Ociperlimab's research:

Ociperlimab has high activity and high affinity with TIGIT; it significantly enhances T cell response and promotes the synthesis and release of T cell IFN-y

Swipe left to see more research

Immune checkpoint inhibitors currently under development for TIGIT

LAG3: An inhibitory immune checkpoint that is expected to be used clinically

• LAG-3 is an inhibitory regulatory molecule that plays an important role in the regulation of T cell activation, enhancement and homeostasis.

  
  

• LAG-3 can inhibit the activity of CD4+ and CD8+ T cells by binding to ligands such as MHC class II molecules and Galectin-3.

  
  

• At present, LAG3 monoclonal antibody is used as a single agent or combined with other therapies for the treatment of a variety of solid tumors.

  
  

LAG3 related research

LAG3 combined with Avelumab

5 cases of PR, 1 case of SD

No drug SAE, no irAE

LAG3, IMP321 combined with Pembrolizumab

The safety features are similar to the KN-042 study

ORR 41.

All PD-L1 groups alleviated

Swipe left to see more research

LAG3 inhibitors currently under development

TIM-3: Inhibition of TIM-3 can enhance antigen-specific immune response

Important research results from Harvard Medical School published in Nature on June 9, 2021:

• Blocking TIM-3 on dendritic cells (DCs) may play a more critical role in enhancing anti-tumor immunity

  
  

• Up-regulation of TIM3 expression in patients who are resistant to PD1 treatment

TIM-3 research:

Future research directions of immunotherapy

Specific double antibody

Immune microenvironment regulation

TIL therapy and neoantigen vaccine

latest progress:

Future direction

Summarize

• Immunotherapy covers the whole process, while benefiting more patients, the new era of immunization 2.

  
  

• Immune checkpoint inhibitor PD-1/PD-L1 still occupies an important position.

  
  

• Specific dual antibodies can stimulate key factors that are guided, and targeted immune microenvironmental drugs are expected to form a breakthrough

• The exploration of TIL therapy and neoantigen vaccines, and individualized immunotherapy go further

  
  

Note: This article is compiled from the live video of CSCO conference by Professor Wang Jie, Cancer Hospital of China Medical University

Speaker introduction

Progress of new immune checkpoint inhibitors

In-depth studies of PD-1/PD-L1 inhibitors have covered the entire course of lung cancer, helping many patients prolong their life cycles

• Establish and improve the prediction system to accurately screen out the population suitable for immunosuppressive agents and long-term survival

• Drug resistance detection and response

• Explore more targets and treatment methods

   

Establish and improve the prediction system to accurately screen out the population suitable for immunosuppressive agents and long-term survival

Drug resistance detection and response

Explore more targets and treatment methods

TIGIT: Immunosuppressive cells in multiple links of the tumor immune cycle

TIGIT: Inhibition of tumor immune circulation

• Can inhibit NK cell-mediated cell killing

• Inhibit CD8 T cell-mediated killing and affect its initiation and differentiation

Can inhibit NK cell-mediated cell killing

Inhibit CD8 T cell-mediated killing and affect its initiation and differentiation

Triagolumab Combination Drug Research

TIGIT inhibitor: In the combined treatment group of Triagolumab and atelizumab, in the PD-L1 TPD>50% group, the ORR data was nearly 3 times higher than that of atelizumab alone

PFS has also improved, and the incidence of adverse reactions in the two groups is relatively close
.

Ociperlimab's research:

Ociperlimab has high activity and high affinity with TIGIT; it significantly enhances T cell response and promotes the synthesis and release of T cell IFN-y
.
The Phase III clinical trials are currently underway
.

Ociperlimab's research:

Ociperlimab has high activity and high affinity with TIGIT; it significantly enhances T cell response and promotes the synthesis and release of T cell IFN-y
.
The Phase III clinical trials are currently underway
.

Swipe left to see more research

Immune checkpoint inhibitors currently under development for TIGIT

LAG3: An inhibitory immune checkpoint that is expected to be used clinically

• LAG-3 is an inhibitory regulatory molecule that plays an important role in the regulation of T cell activation, enhancement and homeostasis.
  In the immune environment where T cells are exhausted, it is often found that LAG-3 and PD-1 are co-expressed

• LAG-3 can inhibit the activity of CD4+ and CD8+ T cells by binding to ligands such as MHC class II molecules and Galectin-3.
  Blocking LAG-3 can restore the activity of CD4+ and CD8+ T cells and restore anti-tumor immunity.
  

• At present, LAG3 monoclonal antibody is used as a single agent or combined with other therapies for the treatment of a variety of solid tumors.
  Colleagues also have the application of LAG-3 bispecific antibodies and the treatment of advanced solid tumors.
  

LAG-3 is an inhibitory regulatory molecule that plays an important role in the regulation of T cell activation, enhancement and homeostasis.
In the immune environment where T cells are exhausted, it is often found that LAG-3 and PD-1 are co-expressed

LAG-3 can inhibit the activity of CD4+ and CD8+ T cells by binding to ligands such as MHC class II molecules and Galectin-3.
Blocking LAG-3 can restore the activity of CD4+ and CD8+ T cells and restore anti-tumor immunity.

At present, LAG3 monoclonal antibody is used as a single agent or combined with other therapies for the treatment of a variety of solid tumors.
Colleagues also have the application of LAG-3 bispecific antibodies and the treatment of advanced solid tumors.

LAG3 related research

LAG3 combined with Avelumab

5 cases of PR, 1 case of SD

No drug SAE, no irAE

LAG3, IMP321 combined with Pembrolizumab

The safety features are similar to the KN-042 study

ORR 41.
7%, mPFS 8.
2m

All PD-L1 groups alleviated

Swipe left to see more research

LAG3 inhibitors currently under development

TIM-3: Inhibition of TIM-3 can enhance antigen-specific immune response

Important research results from Harvard Medical School published in Nature on June 9, 2021:

• Blocking TIM-3 on dendritic cells (DCs) may play a more critical role in enhancing anti-tumor immunity
  .
  

• Up-regulation of TIM3 expression in patients who are resistant to PD1 treatment

Blocking TIM-3 on dendritic cells (DCs) may play a more critical role in enhancing anti-tumor immunity
.

Up-regulation of TIM3 expression in patients who are resistant to PD1 treatment

TIM-3 research:

Future research directions of immunotherapy

Specific double antibody

Immune microenvironment regulation

TIL therapy and neoantigen vaccine

latest progress:

Future direction

Summarize

• Immunotherapy covers the whole process, while benefiting more patients, the new era of immunization 2.
  0 is also coming soon

• Immune checkpoint inhibitor PD-1/PD-L1 still occupies an important position.
  TIGIT, LAG-3, TIM3 and other immune checkpoint inhibitors have poor efficacy.
  Combining PD-1/PD-L1 inhibitors is the future direction

• Specific dual antibodies can stimulate key factors that are guided, and targeted immune microenvironmental drugs are expected to form a breakthrough

• The exploration of TIL therapy and neoantigen vaccines, and individualized immunotherapy go further
  .
  

Immunotherapy covers the whole process, while benefiting more patients, the new era of immunization 2.
0 is also coming soon

Immune checkpoint inhibitor PD-1/PD-L1 still occupies an important position.
TIGIT, LAG-3, TIM3 and other immune checkpoint inhibitors have poor efficacy.
Combining PD-1/PD-L1 inhibitors is the future direction

Specific dual antibodies can stimulate key factors that are guided, and targeted immune microenvironmental drugs are expected to form a breakthrough

The exploration of TIL therapy and neoantigen vaccines, and individualized immunotherapy go further
.

Note: This article is compiled from the live video of CSCO conference by Professor Wang Jie, Cancer Hospital of China Medical University